Adipose MSCs Suppress MCF7 and MDA-MB-231 Breast Cancer Metastasis and EMT Pathways Leading to Dormancy via Exosomal-miRNAs Following Co-Culture Interaction
Related Experiment Video
Updated: Nov 23, 2025

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation
Published on: August 23, 2018
Norlaily Mohd Ali1, Swee Keong Yeap2, Wan Yong Ho3
1Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Cheras 43000, Malaysia.
Abstract:
Globally, breast cancer is the most frequently diagnosed cancer in women, and it remains a substantial clinical challenge due to cancer relapse. The presence of a subpopulation of dormant breast cancer cells that survived chemotherapy and metastasized to distant organs may contribute to relapse. Tumor microenvironment (TME) plays a significant role as a niche in inducing cancer cells into dormancy as well as involves in the reversible epithelial-to-mesenchymal transition (EMT) into aggressive phenotype responsible for cancer-related mortality in patients. Mesenchymal stem cells (MSCs) are known to migrate to TME and interact with cancer cells via secretion of exosome- containing biomolecules, microRNA. Understanding of interaction between MSCs and cancer cells via exosomal miRNAs is important in determining the therapeutic role of MSC in treating breast cancer cells and relapse. In this study, exosomes were harvested from a medium of indirect co-culture of MCF7-luminal and MDA-MB-231-basal breast cancer cells (BCCs) subtypes with adipose MSCs. The interaction resulted in different exosomal miRNAs profiles that modulate essential signaling pathways and cell cycle arrest into dormancy via inhibition of metastasis and epithelial-to-mesenchymal transition (EMT). Overall, breast cancer cells displayed a change towards a more dormant-epithelial phenotype associated with lower rates of metastasis and higher chemoresistance. The study highlights the crucial roles of adipose MSCs in inducing dormancy and identifying miRNAs-dormancy related markers that could be used to identify the metastatic pattern, predict relapses in cancer patients and to be potential candidate targets for new targeted therapy.
Insights
Adipose mesenchymal stem cells (MSCs) induce breast cancer cell dormancy via exosomal microRNAs, inhibiting metastasis and promoting chemoresistance. This discovery offers potential biomarkers for predicting relapse and new therapeutic targets.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Breast cancer relapse is a major challenge, often linked to dormant cancer cells surviving treatment.
- The tumor microenvironment (TME) influences cancer cell dormancy and epithelial-to-mesenchymal transition (EMT), impacting patient mortality.
- Mesenchymal stem cells (MSCs) interact with cancer cells in the TME through secreted exosomes containing microRNAs (miRNAs).
Purpose of the Study:
- To investigate the role of adipose MSCs in inducing dormancy in breast cancer cells (BCCs) via exosomal miRNAs.
- To understand how MSC-derived exosomal miRNAs modulate signaling pathways, cell cycle arrest, and EMT.
- To identify potential miRNA markers for predicting breast cancer metastasis and relapse.
Main Methods:
- Indirect co-culture of MCF7 (luminal) and MDA-MB-231 (basal) breast cancer cells with adipose MSCs.
- Harvesting exosomes from the co-culture medium.
- Analyzing exosomal miRNA profiles and their impact on BCC phenotypes, including dormancy, metastasis, and EMT.
Main Results:
- MSC-derived exosomes induced distinct miRNA profiles in BCCs.
- These exosomal miRNAs modulated signaling pathways, leading to cell cycle arrest and dormancy.
- Breast cancer cells exhibited a shift towards a dormant-epithelial phenotype, with reduced metastasis and increased chemoresistance.
Conclusions:
- Adipose MSCs play a critical role in inducing breast cancer cell dormancy through exosomal miRNAs.
- Identified miRNAs are potential biomarkers for predicting metastatic patterns and cancer relapse.
- These miRNAs represent promising therapeutic targets for novel breast cancer treatments.

